H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $120.00 price target on Cytokinetics (NASDAQ: CYTK).The analyst commented: "Cytokinetics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


